CID-103

About CASI Pharmaceuticals

CASI Pharmaceuticals is an innovative biopharmaceutical company advancing CID-103, a first-in-class anti-CD38 monoclonal antibody, as a potential treatment for antibody-mediated rejection (AMR) in organ transplant patients and for autoimmune diseases like immune thrombocytopenia (ITP). The company operates globally, with a commercial footprint in China for its oncology products, and is led by an experienced management team with deep expertise in drug development and commercialization. CASI's strategy centers on addressing urgent unmet medical needs in transplantation and autoimmunity through a differentiated mechanism of action that targets persistent plasma cells.

About CASI Pharmaceuticals

CASI Pharmaceuticals is an innovative biopharmaceutical company advancing CID-103, a first-in-class anti-CD38 monoclonal antibody, as a potential treatment for antibody-mediated rejection (AMR) in organ transplant patients and for autoimmune diseases like immune thrombocytopenia (ITP). The company operates globally, with a commercial footprint in China for its oncology products, and is led by an experienced management team with deep expertise in drug development and commercialization. CASI's strategy centers on addressing urgent unmet medical needs in transplantation and autoimmunity through a differentiated mechanism of action that targets persistent plasma cells.

Therapeutic Areas